BYOOVIZ

Approval Id: 504a583da21c5607
Drug Approval Canada Name: BYOOVIZ
Product Name: BYOOVIZ
Status: Marketed
Status Date: 2023-03-01
Original Market Date: 2023-03-01
Din: 02525852
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravitreal
Schedule: Schedule D , Prescription
Ahfs: 52:92.00
Atc Original: S01LA04 RANIBIZUMAB
Atc Name: s 01 la 04
Aig Number: 0152224001
Company Name: Samsung Bioepis Co., Ltd.
Company Address: 76, Songdogyoyuk-Ro, Yeonsu-Gu, Incheon, Incheon, Korea, Republic Of, 21987
Company Detail Path: /organization/samsung-bioepis-co-ltd

RANIBIZUMAB

10 MG / ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

504a583da21c5607

Type

Standard